Skip to main content
. 2020 Apr 29;136(2):157–170. doi: 10.1182/blood.2020004850

Figure 4.

Figure 4.

OS of patients with MDS classified according to SF3B1 mutation status. (A) OS of the whole MDS population according to SF3B1 mutation status. Patients with SF3B1-mutated MDS (red curve, n = 769) have a significantly longer survival compared with SF3B1-unmutated MDS patients (blue curve, n = 2555) (P < .001). (B) OS of SF3B1-mutated (red curve, n = 267) and unmutated (blue curve, n = 54) patients with RARS (P < .001). (C) OS of SF3B1-mutated (red curve, n = 171) and unmutated (blue curve, n = 56) patients with RCMD-RS (P = .003). (D) OS of patients with SF3B1-mutated RARS or RCUD (red curve, n = 287) compared to SF3B1-unmutated patients with RARS (blue curve, n = 54) (P < .001). This group overlaps the category of MDS-RS-SLD according to 2016 WHO criteria, except that it comprises occasional patients with SF3B1-mutation and <5% RS. (E) OS of patients with SF3B1-mutated RCMD-RS or RCMD (red curve, n = 189) compared to SF3B1-unmutated patients with RCMD-RS (blue curve, n = 56) (P = .003). This group overlaps the category of MDS-RS-MLD according to 2016 WHO criteria, except that it comprises occasional patients with SF3B1-mutation and <5% RS.(F) OS of SF3B1-mutated (red curve, n = 77) and unmutated patients (blue curve, n = 823) with MDS-EB (P = .34).